ABL1 (ABL proto-oncogene 1)

Furthermore, ponatinib increases chimeric antigen receptor (CAR) TSCM cells by reducing CAR T cell exhaustion, resulting in durable antitumor efficacy. Our results thus implicate ponatinib as therapeutic immunomodulator, inducing TSCM cells for improved antitumor T cell activity.

In conclusion, the DMBA-induced leukemia rat model exhibits a transcriptomic profile that closely mirrors key oncogenic and prognostic features of human leukemia. This model holds significant promise for preclinical studies targeting leukemogenesis and therapeutic intervention strategies.

This case highlights a rare cytogenetic abnormality in CML characterized by acquired pericentric inversion of the derivative chromosome 9 associated with BCR and ABL1 codeletion. Such complex rearrangements likely reflect clonal evolution and may be associated with suboptimal response to first line imatinib therapy. Accurate discrimination between constitutional and acquired inv(9), together with detailed assessment of derivative chromosome 9 integrity, is essential for prognostic stratification. Comprehensive cytogenetic and molecular analyses remain critical for identifying uncommon secondary abnormalities that may influence therapeutic response and clinical outcome in CML.

Dasatinib de-escalation after 100 mg standard dose achieved superior early response, fewer discontinuations, and sustained outcomes versus upfront low-dose therapy. This first Indian study supports de-escalation as an effective, real-world dose-optimization strategy.

The financial and access challenges explored in this study underscore the importance of accelerating more effective and sustainable health policies in the CML field, which include access to the BCR::ABL-1 test with financial accountability.

P1/2, N=12, Completed, CRISPR Therapeutics | Recruiting --> Completed | N=290 --> 12 | Trial completion date: Nov 2030 --> Mar 2026 | Trial primary completion date: May 2030 --> Mar 2026

Survival differences were independent of WHO diagnostic labels, with molecular architecture alone consistently predicting outcomes across all clusters In this Indian MPN cohort, molecular architecture, not WHO label, dictated prognosis. The reproducible impact of high-risk co-mutations demonstrates both the feasibility and need for a genomics-first, tiered classification to guide risk stratification and therapy.

Subsequently, he was started on systemic therapy with dasatinib in combination with the HyperCVAD chemotherapy regimen...Ocular features such as diplopia in the setting of chronic unexplained headache should prompt careful fundus examination, as it may reveal critical clues to underlying intracranial pathology. Early neuroimaging, timely biopsy, and rapid initiation of systemic therapy remain critical for optimizing outcomes.

P1, N=250, Recruiting, Enliven Therapeutics | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

P1/2, N=100, Recruiting, Cardiff University | Not yet recruiting --> Recruiting

P=N/A, N=200, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting